Retraction and republication—Stereotactic body radiotherapy plus pembrolizumab and trametinib versus stereotactic body radiotherapy plus gemcitabine for locally recurrent pancreatic cancer after surgical resection: an open-label, randomised, controlled, phase 2 trial

On July 5, 2021, The Lancet Oncology published a randomised phase 2 trial by Zhu and colleagues1 comparing stereotactic body radiotherapy plus pembrolizumab and trametinib with stereotactic body radiotherapy plus gemcitabine for locally recurrent pancreatic cancer after surgical resection. Following publication, we received letters expressing concerns about the validity of the Kaplan-Meier figures, and the data therein for progression-free survival and overall survival, which seemed to indicate a survival bias.